Company: MVIS
Filing Date: 2025-05-12
Form Type: 10-Q
Source: 0001641172-25-009765
Chunk: 214

Company: MICROVISION, INC.
Filing Date: 2025-05-12
Form: 10-Q
Item: Part I, Item 8
Chunk 214
---
4. Cash used in operating activities resulted primarily from cash used to
fund our net loss, after adjusting for non-cash charges such as interest expense, share-based compensation, depreciation and
amortization charges, unrealized gains and losses, and changes in operating assets and liabilities. The changes in cash used in
operating activities were primarily attributed to decreased operating expenses related to personnel. We expect to make minimum
payments to our contract manufacturing partner in connection with the production of MOVIA sensor inventory of approximately $2.6
million during the remainder of 2025 and 2026 in line with agreed-upon deliveries.

Investing
activities

During
the three months ended March 31, 2025, net cash provided by investing activities was $3.1 million compared to net cash used in investing
activities of $3.3 million during the three months ended March 31, 2024. During the three months ended March 31, 2025, we purchased short-term
investment securities totaling $10.3 million and sold short-term investment securities totaling $13.5 million. During the three months
ended March 31, 2024, we purchased short-term investment securities totaling $7.8 million and sold short-term investment securities totaling
$7.9 million. Purchases of property and equipment during the three months ended March 31, 2025 and 2024 were $0.1 million. During the
three months ended March 31, 2024, we made payments totaling $3.3 million related to the acquisition of Ibeo assets.

Financing
activities

Cash
provided by financing activities totaled $8.2 million during the three months ended March 31, 2025, compared to net cash provided by
financing activities of $21.0 million during the same period of 2024. Proceeds received from stock option exercises totaled $0.1
million during the three months ended March 31, 2024. Net proceeds from issuance of common stock and warrants were $8.2 million
during the three months ended March 31, 2025 compared to $21.0 million during the three months ended March 31, 2024.

The
following is a list of our financing activities during 2025 and 2024.

●In
                                            February 2025, we entered into a securities purchase agreement for the purchase of 5,750,225
                                            shares of our common stock and warrants to